Moderna stock analysis
Moderna (0A45) Share Price & Analysis
0A45 Stock Chart & Stats
- Day’s Range
- $221.60 - $233.00
- 52-Week Range
- $22.25 - $280.82
- Previous Close
- $234.97
- Volume
- N/A
- Average Volume (3M)
- 98.56K
- Market Cap
- $90.38B
- Enterprise Value
- $81.86B
- Total Cash (Recent Filing)
- $5.17B
- Total Debt (Recent Filing)
- $4.18B
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -2.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The higher revenue framework indicates improving commercial execution and demand across Moderna’s portfolio. If sustained, stronger growth can support operating leverage, fund pipeline investment, and reduce dependence on a single seasonal COVID product over the next several quarters.
Oncology Breakthrough
Positive Phase 3 melanoma data provide meaningful validation for Moderna’s individualized cancer-vaccine platform and create a potential commercial franchise beyond respiratory vaccines. The result also supports further oncology development and could broaden the company’s long-term revenue base if approved.
Platform Diversification
Expansion from a predominantly COVID-focused business into influenza and combination respiratory vaccines strengthens product breadth and commercial resilience. Multiple approved products can improve customer relevance, create cross-selling opportunities, and support recurring seasonal revenue across international markets.
Bears Say
Persistent Losses
Large ongoing net and operating losses show that the current revenue base does not yet support Moderna’s cost structure. Continued losses can consume capital, delay sustainable profitability, and limit strategic flexibility unless commercial growth and expense reductions produce durable operating leverage.
Cash Burn
Meaningfully negative operating and free cash flow indicate that Moderna is not currently self-funding its business and pipeline investments. Even with improvement from the prior year, continued burn increases reliance on liquidity and financing until products generate consistently positive cash earnings.
Cost Pressure
Rapidly rising cost of sales threatens margin durability and shows that higher product volume is not automatically translating into stronger economics. Manufacturing-related costs, together with the separate litigation charge, could keep profitability volatile while the portfolio scales and pricing remains competitive.
Moderna News
0A45 FAQ
What was Moderna’s price range in the past 12 months?
What is Moderna’s market cap?
When is Moderna’s upcoming earnings report date?
How were Moderna’s earnings last quarter?
Is Moderna overvalued?
Does Moderna pay dividends?
What is Moderna’s EPS estimate?
How many shares outstanding does Moderna have?
What happened to Moderna’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Moderna?
What is the TipRanks Smart Score and how is it calculated?
Moderna Stock Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Website
- www.modernatx.com
- Address
- 325 Binney Street, Cambridge, MA, 02142, US
Moderna (0A45) Earnings & Revenues
0A45 Company Deck
0A45 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 29% third-quarter revenue growth, a raised full-year revenue outlook of 15% to 25% growth, improved cash and cost frameworks, expanded respiratory-vaccine approvals, and landmark Phase 3 melanoma efficacy results. The main negative developments were the 54% increase in cost of sales, the $900 million litigation charge, the norovirus program missing early-success criteria, slightly lower U.S. COVID vaccination trends, and remaining regulatory and development uncertainty in several programs. Highlights significantly outweighed lowlights.
View all GB:0A45 earnings summaries0A45 Net sales Breakdown
- 61.68% U.S.
- 2.73% Europe
- 35.60% Rest of World
0A45 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 6 | 7 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 6 | 0 | 6 |













